A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)

NCT01896583 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Diarrhea Predominant Irritable Bowel Syndrome

Interventions

DRUG: ASP7147
DRUG: Placebo

Sponsor

Seldar Pharma, Inc.